{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:03:42Z","timestamp":1793754222968,"version":"4.6.1"},"reference-count":77,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2649528","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:44:08Z","timestamp":1775753048000},"page":"1134-1148","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with transfusion-dependent\n                    <b>\n                      <i>\u03b2<\/i>\n                    <\/b>\n                    -thalassemia in the United States"],"prefix":"10.1080","volume":"29","author":[{"given":"Chuka","family":"Udeze","sequence":"first","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gargano","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foluso Joy","family":"Ogunsile","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham","place":["Birmingham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanxin","family":"Li","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghao","family":"Fang","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc","place":["Montreal, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushanth","family":"Jeyakumar","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lopez","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a011700"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050436"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.12.003"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.1624"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12291-013-0376-2"},{"issue":"10","key":"e_1_3_6_7_1","first-page":"1187","article-title":"Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine","volume":"89","author":"Borgna-Pignatti C","year":"2004","unstructured":"Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187\u20131193.","journal-title":"Haematologica"},{"key":"e_1_3_6_8_1","first-page":"249","article-title":"Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF)","volume":"2","author":"De Sanctis V","year":"2004","unstructured":"De Sanctis V, Eleftheriou A, Malaventura C. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev. 2004;2 Suppl 2:249\u2013255.","journal-title":"Pediatr Endocrinol Rev"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S72463"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-300335"},{"key":"e_1_3_6_11_1","article-title":"Betibeglogene autotemcel for beta thalassemia: effectiveness and value; evidence report","author":"Beaudoin F","year":"2022","unstructured":"Beaudoin F, Richardson M, Synnott P. Betibeglogene autotemcel for beta thalassemia: effectiveness and value; evidence report. Inst Clin Econ Rev. 2022.","journal-title":"Inst Clin Econ Rev"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17091"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-025-03961-8"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2235928"},{"key":"e_1_3_6_15_1","volume-title":"CASGEVY (exagamglogene autotemcel), suspension for intravenous infusion","year":"2023","unstructured":"CASGEVY (exagamglogene autotemcel), suspension for intravenous infusion. Boston, MA: Vertex Pharmaceuticals Incorporated; 2023. Available from: https:\/\/www.fda.gov\/media\/174615\/download."},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031054"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1165409"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-292078"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-382408"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309673"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12454577"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02204-0"},{"key":"e_1_3_6_23_1","unstructured":"Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia. Committee Papers 2021. National Institute for Health and Care Excellence; 2021. Available from: https:\/\/www.nice.org.uk\/guidance\/gid-ta10334\/documents\/committee-papers."},{"key":"e_1_3_6_24_1","unstructured":"Vertex Pharmaceuticals Inc. CLIMB THAL-111 Interim Clinical Study Report. 2023."},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.282"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238793"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dew123"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jex012"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12224"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b4229"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v100.1.17"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.09.024"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200725040-00005"},{"key":"e_1_3_6_34_1","unstructured":"National Vital Statistics System Mortality. Life tables for males and females. United States National Center for Health Statistics. 2018. Available from: https:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr69\/nvsr69-12-508.pdf."},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(01)00879-8"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107943"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-019-01136-0"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-020-02650-y"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-012-0008-2"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27296"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-005-1949-6"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12978-019-0706-9"},{"key":"e_1_3_6_43_1","unstructured":"Micromedex\u00ae RED BOOK\u00ae: Merative. [Available from: https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/."},{"key":"e_1_3_6_44_1","unstructured":"A safety and efficacy study evaluating CTX001 in subjects with transfusion-dependent \u03b2-thalassemia [CTX001-111]. Bethesda MD: U.S. National Library of Medicine. 2018. Available from: https:\/\/clinicaltrials.gov\/show\/NCT03655678."},{"key":"e_1_3_6_45_1","unstructured":"Medicare Inpatient Hospitals - by Provider and Service dataset: centers for Medicare and Medicaid Services. Available from: https:\/\/data.cms.gov\/provider-summary-by-type-of-service\/medicare-inpatient-hospitals\/medicare-inpatient-hospitals-by-provider-and-service."},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25429"},{"key":"e_1_3_6_47_1","volume-title":"Guidelines for the management of Transfusion Dependent Thalassemia (TDT)","author":"Farmakis D","year":"2021","unstructured":"Farmakis D, Porter JTA, Cappellini MD. Guidelines for the management of Transfusion Dependent Thalassemia (TDT). 4th ed. Nicosia, Cyprus: Thalassemia International Federation; 2021.","edition":"4"},{"key":"e_1_3_6_48_1","unstructured":"Product Information for Exjade: European Medicines Agency. [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/exjade-epar-product-information_en.pdf."},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.07.020"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-010-1419-7"},{"key":"e_1_3_6_51_1","unstructured":"Product Information for Ferriprox: European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ferriprox-epar-product-information_en.pdf."},{"key":"e_1_3_6_52_1","doi-asserted-by":"crossref","unstructured":"Economic costs of diabetes in the US in 2017. American Diabetes Association; Available from: https:\/\/diabetesjournals.org\/care\/article\/41\/5\/917\/36518\/Economic-Costs-of-Diabetes-in-the-U-S-in-2017.","DOI":"10.2337\/dci18-0007"},{"key":"e_1_3_6_53_1","unstructured":"Paying for treatments: alliance for Fertility Preservation. Available from: https:\/\/www.allianceforfertilitypreservation.org\/paying-for-treatments\/."},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000849668.07702.9f"},{"key":"e_1_3_6_55_1","unstructured":"Physician Fee Schedule.: Centers for Medicare and Medicaid Services. Available from: https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search."},{"key":"e_1_3_6_56_1","unstructured":"National Inpatient Sample: Healthcare Cost and Utilization Project. 2015. Available from: https:\/\/hcup-us.ahrq.gov\/nisoverview.jsp."},{"key":"e_1_3_6_57_1","unstructured":"Price indexes for personal consumption expenditures by major type of product. Personal Consumption Expenditure (PCE) Price Index Health Care: US Bureau of Economic Analysis. Available from: https:\/\/apps.bea.gov\/iTable\/iTable.cfm?1921=underlying&isuri=1&reqid=19&step=2#1921=underlying&isuri=1&reqid=19&step=2."},{"key":"e_1_3_6_58_1","first-page":"23","article-title":"Crizanlizumab, voxelotor, and L-glutamine for sickle cell disease: effectiveness and value","author":"Bradt P","year":"2020","unstructured":"Bradt P, Spackman E, Synnott P, et al. Crizanlizumab, voxelotor, and L-glutamine for sickle cell disease: effectiveness and value. Inst Clin Econ Rev. 2020:23.","journal-title":"Inst Clin Econ Rev"},{"key":"e_1_3_6_59_1","unstructured":"Table B-3. Average hourly and weekly earnings of all employees on private nonfarm payrolls by industry sector seasonally adjusted: US Bureau of Labor Statistics. Available from: https:\/\/www.bls.gov\/news.release\/empsit.toc.htm."},{"key":"e_1_3_6_60_1","unstructured":"Normal retirement age: Social Security Administration. Available from: https:\/\/www.ssa.gov\/oact\/progdata\/nra.html."},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162380"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.9.1162"},{"key":"e_1_3_6_63_1","volume-title":"Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent \u03b2-Thalassemia. 66th Meeting of the International Conference on American Society of Hematology (ASH)","author":"Frangoul H","unstructured":"Frangoul H, Locatelli F. Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent \u03b2-Thalassemia. 66th Meeting of the International Conference on American Society of Hematology (ASH), 2024 December 7\u201310; San Diego, CA."},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26798"},{"key":"e_1_3_6_65_1","volume-title":"ISPOR Europe","author":"Udeze C","year":"2023","unstructured":"Udeze C, Jeyakumar S, Fang H, et al. Model-projected long-term clinical outcomes of Exagamglogene Autotemcel (Exa-cel) gene-edited therapy in patients with transfusion-dependent \u03b2-thalassemia in the United Kingdom. ISPOR Europe; November 12\u201315; Copenhagen, Denmark; 2023."},{"key":"e_1_3_6_66_1","volume-title":"ISPOR Europe","author":"Udeze C","year":"2024","unstructured":"Udeze C, Gargano M, Kaindl L, et al. Model-projected survival and lifetime clinical outcomes of Exagamglogene Autotemcel (Exa-cel) in patients with transfusion-dependent beta-thalassemia in Canada. ISPOR Europe; Nov 17\u201320, Barcelona, Spain; 2024."},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2021.1922028"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.02.001"},{"key":"e_1_3_6_69_1","unstructured":"ZYNTEGLO (betibeglogene autotemcel) suspension for intravenous infusion Bluebird bio Inc. 2022. Available from: https:\/\/www.fda.gov\/media\/160991\/download."},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113206"},{"key":"e_1_3_6_71_1","unstructured":"CADTH Reimbursement Review - luspatercept (Reblozyl) 2021. CADTH. [Available from https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/complete\/SR0669%20Reblozyl-combined-final.pdf."},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a011643"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.4103\/ajts.AJTS_71_16"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.099747"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01786-4"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-022-01215-1"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2016.10.012"},{"key":"e_1_3_6_78_1","unstructured":"Hospital adjusted expenses per inpatient day. Kaiser Family Foundation. 2021. Available from https:\/\/www.kff.org\/health-costs\/state-indicator\/expenses-per-inpatient-day\/."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2649528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:44:12Z","timestamp":1775753052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2649528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2649528"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2649528","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}